IL313289A - Immunomodulatory proteins ICOS ligand variants and uses thereof - Google Patents

Immunomodulatory proteins ICOS ligand variants and uses thereof

Info

Publication number
IL313289A
IL313289A IL313289A IL31328924A IL313289A IL 313289 A IL313289 A IL 313289A IL 313289 A IL313289 A IL 313289A IL 31328924 A IL31328924 A IL 31328924A IL 313289 A IL313289 A IL 313289A
Authority
IL
Israel
Prior art keywords
polypeptide
variant icosl
variant
domain
fold
Prior art date
Application number
IL313289A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of IL313289A publication Critical patent/IL313289A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL313289A 2016-04-15 2017-04-14 Immunomodulatory proteins ICOS ligand variants and uses thereof IL313289A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662323608P 2016-04-15 2016-04-15
US201662394745P 2016-09-14 2016-09-14
US201662410842P 2016-10-20 2016-10-20
US201762472568P 2017-03-16 2017-03-16
US201762475162P 2017-03-22 2017-03-22
PCT/US2017/027811 WO2017181148A2 (en) 2016-04-15 2017-04-14 Icos ligand variant immunomodulatory proteins and uses thereof

Publications (1)

Publication Number Publication Date
IL313289A true IL313289A (en) 2024-08-01

Family

ID=60042799

Family Applications (2)

Application Number Title Priority Date Filing Date
IL262365A IL262365B2 (en) 2016-04-15 2017-04-14 Immunomodulatory proteins ICOS ligand variants and uses thereof
IL313289A IL313289A (en) 2016-04-15 2017-04-14 Immunomodulatory proteins ICOS ligand variants and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL262365A IL262365B2 (en) 2016-04-15 2017-04-14 Immunomodulatory proteins ICOS ligand variants and uses thereof

Country Status (13)

Country Link
US (3) US10882914B2 (enURL)
EP (1) EP3442999A2 (enURL)
JP (3) JP7058609B2 (enURL)
KR (4) KR102536850B1 (enURL)
CN (1) CN110088126A (enURL)
AU (2) AU2017250358B2 (enURL)
BR (1) BR112018070934A2 (enURL)
CA (1) CA3019199A1 (enURL)
IL (2) IL262365B2 (enURL)
MA (1) MA43551A (enURL)
MX (2) MX2018012472A (enURL)
SG (1) SG11201808457PA (enURL)
WO (1) WO2017181148A2 (enURL)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-PVRIG antibodies and methods of use
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
CN108884139A (zh) 2015-11-02 2018-11-23 戊瑞治疗有限公司 Cd80胞外域多肽及其在癌症治疗中的用途
KR20250024105A (ko) 2016-04-15 2025-02-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
EP3442999A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US20230138915A1 (en) * 2016-10-19 2023-05-04 Cellectis TAL- effector nuclease (TALEN) -MODIFIED ALLOGENIC CELLS SUITABLE FOR THERAPY
US20200040059A1 (en) * 2016-10-20 2020-02-06 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc CD80 Variant Immune Modulator Proteins and Uses Thereof
AU2018258661A1 (en) 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
EP3634466A4 (en) * 2017-06-06 2021-03-24 Relinia, Inc. MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
KR20250034197A (ko) * 2017-10-18 2025-03-10 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
BR112020013236A2 (pt) * 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN118580363A (zh) 2018-03-27 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
US12326457B2 (en) 2018-05-24 2025-06-10 Rush University Medical Center ICOSL for use as a renal therapeutic
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
WO2020154640A1 (en) * 2019-01-24 2020-07-30 University Of Central Florida Research Foundation, Inc. Compositions and methods for stimulating natural killer cells
EP3930733A4 (en) * 2019-03-01 2023-03-15 Achelois Biopharma, Inc. METHODS OF MODULATING CD160 FUNCTION IN THE ANTIGEN-SPECIFIC IMMUNE CELL AND USES THEREOF
JP7602475B2 (ja) * 2019-03-08 2024-12-18 オートラス リミテッド 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
MX2021012607A (es) * 2019-04-17 2022-03-11 Alpine Immune Sciences Inc Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
KR20220035471A (ko) * 2019-07-19 2022-03-22 메모리얼 슬로안 케터링 캔서 센터 면역치료법을 위한 융합 폴리펩티드
MX2022010467A (es) * 2020-02-25 2022-12-15 Momenta Pharmaceuticals Inc Enzimas para la sialilación de glicanos.
AU2021267276B2 (en) 2020-05-08 2024-10-24 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
CN118843469A (zh) * 2022-01-28 2024-10-25 北卡罗来纳大学教堂山分校 自然杀伤t细胞及其使用方法
JP2025508961A (ja) * 2022-03-03 2025-04-10 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 抗ＣＤ１９および抗ＣＤ７９ｂキメラ抗原受容体ならびにその使用方法
KR20230155960A (ko) * 2022-05-03 2023-11-13 고려대학교 산학협력단 Icos와의 결합력이 향상된 icos-l 변이체
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5580756A (en) 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
AU674492B2 (en) 1991-05-06 1997-01-02 United States of America, as represented by the Department of Health and Human Services, The Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
EP0783573B1 (en) 1994-09-23 2005-12-21 The University of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
EP0784483B1 (en) 1994-10-03 2000-11-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5767071A (en) 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたａａｖベクター
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
AU8828598A (en) 1997-08-15 1999-03-08 Rubicon Laboratory, Inc. Retrovirus and viral vectors
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
EP1102790B1 (en) 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
DE69941905D1 (de) 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IL144056A0 (en) 1999-01-15 2002-04-21 Genentech Inc Polypeptide variants with altered effector function
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
WO2001021796A2 (en) 1999-09-21 2001-03-29 Genetics Institute, Inc. Gl50 molecules and uses therefor
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
WO2001045737A2 (en) 1999-12-22 2001-06-28 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
DE60107203T3 (de) 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
EP1360290A2 (en) 2000-06-23 2003-11-12 Maxygen, Inc. Co-stimulatory molecules
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
AU2002256510B2 (en) 2001-05-11 2007-08-30 Wellstat Biologics Corporation Oncolytic virus therapy
US7553939B2 (en) 2001-06-29 2009-06-30 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
JP2004537305A (ja) 2001-07-11 2004-12-16 ユニバーシティー オブ マイアミ 腫瘍細胞の処置のための組換えｖｓｖ
CN1304559C (zh) 2001-10-09 2007-03-14 杭州康科生物技术有限公司 表达热休克蛋白的溶瘤微生物及其应用
US7247615B2 (en) 2001-11-30 2007-07-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptide agonists of prostate-specific antigen and uses therefor
US7235631B2 (en) 2002-02-07 2007-06-26 Mayo Foundation For Medical Education And Research ICOS mutants
CA2479763A1 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US8535672B2 (en) 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
EP1539230A4 (en) 2002-06-21 2007-10-31 Wellstat Biologics Corp ADMINISTRATION OF THERAPEUTIC VIRUSES
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20050260601A1 (en) 2002-09-09 2005-11-24 Whitt Michael A Recombinant mutants of rhabdovirus and methods of use thereof
NZ556544A (en) 2002-10-03 2008-11-28 Wyeth Corp Human papillomavirus polypeptides and immunogenic compositions
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SI2289936T1 (sl) 2002-12-16 2017-10-30 Genentech, Inc. Imunoglobulinske variante in njihove uporabe
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
ATE539162T1 (de) 2003-03-27 2012-01-15 Ottawa Hospital Res Inst Mutierte viren der vesikulären stomatitis und deren verwendung
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
CN102174574B (zh) 2003-09-30 2016-08-03 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
EP1694852B1 (en) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP1919950A1 (en) 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7550296B2 (en) 2004-12-01 2009-06-23 Bayer Schering Pharma Ag Generation of replication competent viruses for therapeutic use
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US20070020238A1 (en) 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
CN101495126B (zh) 2005-06-23 2016-01-06 休斯顿大学 Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
KR101263079B1 (ko) 2005-07-18 2013-05-09 암젠 인크 인간 항-ｂ7ｒｐ1 중화 항체
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
DK2048955T3 (da) 2006-07-21 2013-09-02 California Inst Of Techn Målrettet gen-tilførsel til dendrit-cellevaccination
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
WO2008140621A2 (en) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
CA2690627C (en) 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
CA2693707A1 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
CA2693623A1 (en) 2007-07-18 2009-01-22 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
TWI563002B (en) 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
US8426561B2 (en) 2007-11-27 2013-04-23 Francina C. Chahal Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
HRP20180184T1 (hr) 2007-12-11 2018-04-06 The University Of North Carolina At Chapel Hill Retrovirusni vektori s modificiranim polipurinskim nizom
ES2951646T3 (es) 2008-02-21 2023-10-24 Burnham Institute For Medical Res Métodos y composiciones relacionados con péptidos y proteínas con elementos C-terminales
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009139921A2 (en) 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
ES2866623T3 (es) 2008-11-24 2021-10-19 Massachusetts Inst Technology Métodos y composiciones para el suministro localizado de nanopartículas a un tumor
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US20150359909A1 (en) 2009-07-16 2015-12-17 University College Cork-National University Of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
EP2283810A1 (en) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
EA032403B1 (ru) 2009-07-24 2019-05-31 Иммьюн Дизайн Корп. Лентивирусные векторы, псевдотипированные гликопротеином оболочки вируса синдбис
EP3381937A3 (en) 2009-08-13 2018-10-31 The Johns Hopkins University Methods of modulating immune function
ES2681214T3 (es) 2009-09-30 2018-09-12 Memorial Sloan-Kettering Cancer Center Inmunoterapia de combinación para el tratamiento del cáncer
AU2011212794B2 (en) 2010-02-04 2014-06-26 The Trustees Of The University Of Pennsylvania ICOS critically regulates the expansion and function of inflammatory human Th17 cells
EP2545073B1 (en) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
US9637557B2 (en) 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
US9029315B2 (en) 2010-11-11 2015-05-12 The University Of Hong Kong Soluble PD-1 variants, fusion constructs, and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
SG194099A1 (en) 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
US8609625B2 (en) 2011-06-24 2013-12-17 Taipei Veterans General Hospital Method for enhancing immune response in the treatment of infectious and malignant diseases
US9428574B2 (en) * 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
PT3357511T (pt) 2011-06-30 2020-07-23 Genzyme Corp Inibidores da ativação de células t
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
EA037979B1 (ru) 2012-02-27 2021-06-18 Амуникс Оперейтинг Инк. Композиции конъюгата xten и способы их получения
DK2831095T3 (en) 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN104302309B (zh) 2012-05-11 2017-07-28 米迪缪尼有限公司 Ctla‑4变体
JP2016500251A (ja) 2012-12-03 2016-01-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強
BR112015013127A2 (pt) 2012-12-04 2017-09-26 Oncomed Pharm Inc imunoterapia com agentes de ligação
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US20160017041A1 (en) 2013-03-15 2016-01-21 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
AU2014257549B2 (en) 2013-04-23 2019-04-18 Elasmogen Limited Synthetic library of specific binding molecules
WO2014198002A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute A bacterium producing an interferon binding protein and uses thereof
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
US20160271218A1 (en) 2013-06-27 2016-09-22 Mor Research Applications Ltd. Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015120363A1 (en) 2014-02-10 2015-08-13 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
EP3122781B1 (en) 2014-03-28 2020-01-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
EP3169352A1 (en) 2014-07-15 2017-05-24 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
DK3552615T3 (da) 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
CA2994927A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University High affinity pd-1 agents and methods of use
SG10201901735XA (en) 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
CA2966988A1 (en) 2014-11-06 2016-05-12 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
EP3020816A1 (en) 2014-11-11 2016-05-18 University College Cork Bacterial mediated gene therapy
WO2016118577A1 (en) 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
AU2016240411A1 (en) 2015-04-02 2017-10-12 Cancure Limited Agents and compositions for eliciting an immune response
WO2016164428A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
PL3283508T3 (pl) * 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
IL290571B2 (en) 2015-07-30 2023-03-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
US20180221503A1 (en) 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
CA2993478A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
WO2017048878A1 (en) * 2015-09-14 2017-03-23 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
KR20180053752A (ko) 2015-10-02 2018-05-23 심포젠 에이/에스 항-pd-1 항체 및 조성물
US11684656B2 (en) 2015-11-04 2023-06-27 Taipei Veterans General Hospital Combination therapy for malignant diseases
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
EP3442999A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
KR20250024105A (ko) 2016-04-15 2025-02-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
JP2019522466A (ja) 2016-05-18 2019-08-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US20200040059A1 (en) 2016-10-20 2020-02-06 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
KR20240123406A (ko) 2017-03-16 2024-08-13 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
KR20250034197A (ko) 2017-10-18 2025-03-10 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
MX2021012607A (es) 2019-04-17 2022-03-11 Alpine Immune Sciences Inc Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.

Also Published As

Publication number Publication date
KR102536850B1 (ko) 2023-05-26
AU2017250358B2 (en) 2023-06-01
US20240409660A1 (en) 2024-12-12
NZ746741A (en) 2023-12-22
BR112018070934A2 (pt) 2019-02-26
JP2019514361A (ja) 2019-06-06
MX2022009923A (es) 2022-09-09
US12110339B2 (en) 2024-10-08
MX2018012472A (es) 2019-08-12
KR20230051602A (ko) 2023-04-18
SG11201808457PA (en) 2018-10-30
CA3019199A1 (en) 2017-10-19
WO2017181148A2 (en) 2017-10-19
EP3442999A2 (en) 2019-02-20
US20210188995A1 (en) 2021-06-24
JP2022064959A (ja) 2022-04-26
JP7623967B2 (ja) 2025-01-29
MA43551A (fr) 2018-11-07
AU2023202718A1 (en) 2023-05-18
IL262365A (en) 2018-11-29
US10882914B2 (en) 2021-01-05
WO2017181148A3 (en) 2018-02-01
JP7058609B2 (ja) 2022-04-22
KR20250095754A (ko) 2025-06-26
IL262365B1 (en) 2024-07-01
KR20190005879A (ko) 2019-01-16
IL262365B2 (en) 2024-11-01
US20170320959A1 (en) 2017-11-09
CN110088126A (zh) 2019-08-02
KR20230051601A (ko) 2023-04-18
JP2024138024A (ja) 2024-10-07
AU2017250358A1 (en) 2018-10-18
KR102824067B1 (ko) 2025-06-23

Similar Documents

Publication Publication Date Title
US12110339B2 (en) ICOS ligand variant immunomodulatory proteins and uses thereof
US11498967B2 (en) CD80 variant immunomodulatory proteins and uses thereof
US20230381229A1 (en) Cd155 variant immunomodulatory proteins and uses thereof
EP3596116B1 (en) Pd-l1 variant immunomodulatory proteins and uses thereof
US11613566B2 (en) Variant ICOS ligand immunomodulatory proteins and related compositions and methods
US11834490B2 (en) CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) CD155 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) PD-L2 variant immunomodulatory proteins and uses thereof